Observations placeholder
Mycophenolate Mofetil and Mycophenolic acid
Identifier
019560
Type of Spiritual Experience
Background
A description of the experience
Mycophenolic acid, less accurately called mycophenolate, is an immunosuppressant drug used to prevent rejection in organ transplantation. It inhibits an enzyme needed for the growth of T cells and B cells. It was initially marketed as the prodrug mycophenolate mofetil (MMF) to improve oral bioavailability. More recently, the salt mycophenolate sodium has also been introduced. Mycophenolate mofetil is commonly marketed under the trade name CellCept ( for oral use), and mycophenolate sodium as Myfortic .
Adverse effects
Common adverse drug reactions (≥1% of patients) associated with mycophenolate therapy include diarrhea, nausea, vomiting, joint pain; infections, leukopenia, and/or anemia reflect the immunosuppressive and myelosuppressive nature of the drug. Mycophenolate sodium is also commonly associated with fatigue, headache, cough and/or breathing issues. Intravenous (IV) administration of mycophenolate mofetil is also commonly associated with thrombophlebitis and thrombosis. Infrequent adverse effects (0.1–1% of patients) include esophagitis, gastritis, gastrointestinal tract hemorrhage, and/or invasive cytomegalovirus (CMV) infection.More rarely, pulmonary fibrosis or various neoplasia occur: melanoma, lymphoma, other malignancies having an occurrences of 1 in 20 to 1 in 200, depending on the type, with neoplasia in the skin being the most common site. Several cases of pure red cell aplasia (PRCA) have also been reported
The U.S. Food and Drug Administration (FDA) has issued an alert that patients on mycophenolate mofetil and mycophenolic acid are at increased risk of opportunistic infections, such as activation of latent viral infections, including shingles, other herpes infections, cytomegalovirus, and BK virus associated nephropathy. In addition the FDA is investigating 16 patients that developed a rare neurological disease while taking the drug. This is a viral infection known as progressive multifocal leukoencephalopathy; it attacks the brain and is usually fatal.
Mycophenolic acid is associated with miscarriage and congenital malformations when used during pregnancy, and should be avoided whenever possible by women trying to conceive
On Dec, 15, 2015: 1,267 people reported to have side effects when taking Mycophenolic acid. Among them, 6 people (0.39%) have Hallucination.
On Dec, 31, 2016 22,565 people reported to have side effects when taking Mycophenolate Mofetil. Among them, 61 people (0.27%) have Hallucination
Time on Mycophenolate mofetil when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 95.74% | 4.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Mycophenolate mofetil :
| Female | Male | |
| Hallucination | 14.44% | 85.56% |
Age of people who have Hallucination when taking Mycophenolate mofetil :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 0.00% | 1.11% | 8.89% | 56.67% | 11.11% | 22.22% |
On Jan, 4, 2016: 14,624 people reported to have side effects when taking Mycophenolate mofetil. Among them, 636 people (4.35%) have Death.
On Jan, 7, 2016: 1,268 people reported to have side effects when taking Mycophenolic acid. Among them, 18 people (1.42%) have Death.
Time on Mycophenolic acid when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 40.00% | 40.00% | 20.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Mycophenolic acid :
| Female | Male | |
| Death | 18.75% | 81.25% |